ORBIS Compliance

Anvisa Unveils New SOP to Enhance Medicine Evaluation Processes

Published /Brazil

Overview

Anvisa has recently issued Standard Operating Procedure (SOP) RDC nº 823/2023, launching a pilot project aimed at optimizing the evaluation process based on risk criteria for both medicine registration documentation and post-registration changes.

The primary objective of this initiative is to provide clear guidelines for the assessment and decision-making processes concerning registration requests and modifications to medications. These guidelines are rooted in risk criteria, which evaluate the level of risk associated with proposed medications or changes.

This streamlined approach seeks to enhance efficiency and effectiveness in evaluating medicines, thereby optimizing time and resource allocation throughout the registration and post-registration modification processes. Key aspects include:

  • Guidelines: Defined rules and principles governing the evaluation and decision-making process, encompassing document submission requirements, evaluation factors, and pendency management protocols.
  • Registration and Modifications: Refers to requests for initial medicine registration and subsequent changes to registered medicines, encompassing alterations in formulation, manufacturing processes, and labeling.
  • Risk Criteria: Factors considered during evaluation, including the severity of the treated condition, potential side effects, and the target patient population.

The SOP specifies that these measures will take effect on May 25th, 2027. Additionally, it outlines the roles and responsibilities of managers, specialists, and technicians in evaluating and classifying pending issues based on risk. This structured framework aims to ensure rigorous yet efficient evaluation processes for medicines under regulatory review.

Regulatory Impact

  • Top Priority: Yes
  • Type of Certificate: Yes
  • Spectrum Bands: No
  • Import Changes HS Codes: No
  • Standard Changes: No
  • Product Changes: Yes
  • Label Changes: No

Link to Source - https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2024/anvisa-publica-procedimento-operacional-padrao-para-area-de-medicamentos

Regulatory Impact

Impact TypeStatus
Top Priority
Type Certificate
Spectrum Bands
Import Changes (HS Codes)
Standard Changes
Product Changes
Label Changes

Brazil Quick Facts

Regulatory AgencyANATEL (Agência Nacional de Telecomunicações)
Certification TypeMandatory
License ValidityTechnical compliance certificate: 2 to 3 years
Application LanguagePortuguese
Legal License HolderRequired
In-country Testing RequirementRequires testing

Talk to our Experts

Let us clarify how this news impacts you. Fill the form below and we will get back to you within 24 hours.

Gain comprehensive insights and the latest regulatory updates from around the globe with ORBIS Compliance's product certification management resources. Discover how to utilize these tools by completing our brief contact form for more information.